Azithromycin and the Outcome of Treated COVID-19 Patients: A Hospital-Based Study



DOI: https://doi.org/10.25077/jom.7.1.76-81.2022


Author(s)

Elly Usman (Department of Pharmacology and Therapeutics, Faculty of Medicine, Andalas University) Orcid ID

Abstract


COVID-19 is an infectious disease that has been declared a pandemic. Currently, there is no validated pharmacological treatment for use in COVID-19 disease and is still in the clinical trial stage. The aim of this study to determine the association of azithromycin and the outcome of treated COVID-19 patients. This study used a retrospective cohort.  The number of samples in this study were 40 subjects in each group of azithromycin and non-azithromycin. The research sample was all COVID-19 patients who were treated at Dr. M Djamil Hospital Padang with moderate and severe grades receiving treatment with azithromycin and non-azithromycin. The inclusion criteria in this study were moderate and severe COVID-19 patients and data related to research variables were complete and well-documented. Sampling technique with convenience sampling. Data analysis was performed using the Chi-square test. P < 0.05 was significant, and the data were analyzed using the SPSS version 21.0 program. The mortality of COVID-19 patients in patients receiving azithromycin therapy (80.0%) compared to non-azithromycin (85.0%). The results of the statistical test showed that there was no relationship of azithromycin administration with the outcome of COVID-19 patients (p>0.05), with OR (0.71, 95% CI 0.22-2.26). In this study, it is hoped that the decision on the use of azithromycin should consider the potential benefits and risks, evaluated that the possibility of the drug being effective is greater than the risk to the patient.

Keywords


Azithromycin, COVID-19, outcome

Full Text:

PDF

References


D.H. Tran, R. Sugamata, T. Hirose, S. Suzuki, Y. Noguchi, A. Sugawara, et al, “Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process”, J Antibiot (Tokyo), 2019, 72(10), pp. 759-768.

E. Bosseboeuf, M. Aubry, T. Nhan, J.J. de Pina, J.M. Rolain, D. Raoult, D. Musso, “Azithromycin inhibits the replication of zika virus”, J Antivir Antiretrovir, 2018, 10(1), pp. 6-11.

J.M. Molina, C. Delaugerre, J. Le Goff, B. Mela-Lima, D. Ponscarme, L. Goldwirt, N. de Castro, “No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection”, Med Mal Infect, 2020, 50, pp. 384.

L. Ayerbe, C. Risco-Risco, I. Forgnone, M. Pérez-Piñar, S. Ayis S, “Azithromycin in patients with COVID-19: a systematic review and meta-analysis”, J Antimicrob Chemother, 2022, 77(2), pp. 303-309.

L.B. Bacharier, T.W. Guilbert, D.T. Mauger, et al, “Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial”, JAMA, 2016, 315(4), pp. 419.

L.S. Nguyen, C. Dolladille, M.D. Drici, C. Fenioux, J. Alexandre, J.P. Mira, et al, “Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: An analysis of the world health organization pharmacovigilance database”, Circulation, 2020, 142, pp. 303–305.

P. Gautret, J.C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, et al, “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”, Int J Antimicrob Agents, 2020, 105949, pp. 1-6.

Q. Ye, B. Wang, J. Mao, “The pathogenesis and treatment of the `Cytokine Storm' in COVID-19”, J Infect, 2020, 80(6), pp. 607–613.

T. Fiolet, A. Guihur, M. Rebeaud, “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis”, Clin Microbiol Infect, 2021, 27, pp. 19–27.

T.F. O’Connell, C.J. Bradley, A.E. Abbas et al, “Hydroxychloroquine/azithromycin therapy and QT prolongation in hospitalized patients with COVID-19”, JACC Clin Electrophysiol, 2021, 7, pp. 16–25.

Y. Zhang, J. Dai, H. Jian, J. Lin, “Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta-analysis of randomized controlled trials”, Microbiol Immunol, 2019, 63, pp. 343–349.


Article Metrics

This article has been read : 76 times
PDF file viewed/downloaded : 30 times

Copyright & License


Copyright (c) 2022 Elly Usman

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Published by:
Undergraduate Program of Midwifery
Faculty of Medicine - Universitas Andalas - Indonesia
Faculty of Medicine, Universitas Andalas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.